Blood Res.  2016 Mar;51(1):66-66. 10.5045/br.2016.51.1.66.

Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?

• Palombi M
• Scaramucci L
• Giovannini M
• Trawinska
• Niscola P
• de Fabritiis P

• KMID: 2172749
• DOI: http://doi.org/10.5045/br.2016.51.1.66

Abstract

No abstract available.

MeSH Terms

Thrombocytopenia*
Rituximab

Reference

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115:168–186. PMID: 19846889.

2. Ozkan MC, Sahin F, Saydam G. Immune thrombocytopenic purpura: new biological therapy of an old disease. Curr Med Chem. 2015; 22:1956–1962. PMID: 25787847.

3. Godeau B, Stasi R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia? Presse Med. 2014; 43:e79–e85. PMID: 24636845.

4. Kim YK, Lee SS, Jeong SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015; 50:19–25. PMID: 25830126.

5. Scaramucci L, Giovannini M, Niscola P, Tendas A, Perrotti A, De Fabritiis P. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus. 2014; 12:605–607. PMID: 25351191.